Status:
COMPLETED
Candesartan and Candesartan/ Hydrochlorothiazide in the Treatment of Patients With Hypertension and LVH
Lead Sponsor:
AstraZeneca
Conditions:
Essential Hypertension
Left Ventricular Hypertrophy
Brief Summary
The CandLE study with at maximum daily dose of 32 mg candesartan or 16/12.5 mg candesartan/hydrochlorothiazide has the objective to evaluate under naturalistic conditions, i.e. under routine medical c...
Eligibility Criteria
Inclusion
- essential hypertension
- left ventricular hypertrophy
- under candesartan treatment
Exclusion
Key Trial Info
Start Date :
January 1 2007
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2007
Estimated Enrollment :
686 Patients enrolled
Trial Details
Trial ID
NCT00607633
Start Date
January 1 2007
End Date
October 1 2007
Last Update
February 6 2008
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.